Curiosity: Running BE studies with more than 2 arms [Design Issues]

posted by jag009  – NJ, 2012-06-11 17:01 (5117 d 16:25 ago) – Posting: # 8683
Views: 12,719

Hi everyone,

I have a question. If there is a FDA a draft BE guidance for a product specifing the type of 2 way crossover studies that need to be conducted:
  1. 2-way crossover (Test vs Reference) fasting
  2. 2-way crossover (Test vs Reference) fed
What if we end up running a 4-way crossover involving 3 test formulations vs 1 Reference for each study? Everything will be the same except for 2 extra arms. The reason we are doing this is because we want to bypass the pilot study.

Would that be doable? The only issue I can see (beside the cost) is the ethical issue because we will (obviously) draw more blood samples per subject, and may have a larger sample size due to potential dropouts since the length of the study is doubled.

I believe FDA allows the use of an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations.

Do you think the agency will have an issue with the approach?

Thanks

John

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
126 visitors (0 registered, 126 guests [including 20 identified bots]).
Forum time: 09:27 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5